Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06722183 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

Study acronym: FUTURE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 2025 to Dec 16, 2025
    • Study sites: 11 to 10
    • Primary and study completion dates: Sep 2027 to Mar 2028
    v4
  2. Start date: Mar 2025 to Jun 2025
    • Primary and study completion dates: Jun 2027 to Sep 2027
    • Eligibility criteria expanded, about 11 words
    v3
  3. Study title shortened, about 6 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.
Trial Details
NCT Number NCT06722183
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler
Conditions
(from sponsor)		 Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov